# Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Source: https://onco.cc/trials/nct06155383/  
OnCo record `nct06155383` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Capecitabine, Oxaliplatin, Disitamab vedotin and Toripalimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. is a phase 2 interventional study registered as NCT06155383 by RemeGen Co., Ltd., with 90 participants planned, started 2023-11-27 and due to reach its primary completion in 2025-01-31. Interventions recorded: Capecitabine, oxaliplatin, Disitamab Vedotin and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06155383
- Phase: 2
- Setting: A Phase II Study of Perioperative Disitamab Vedotin Plus Toripalimab and XELOX Versus Disitamab Vedotin Plus Toripalimab Versus XELOX in Subjects With HER2-expressing Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06155383: https://clinicaltrials.gov/study/NCT06155383

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06155383.json